Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for

Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for

Filed under: drug treatment news 2011

NEW YORK, Sept. 12, 2012 (GLOBE NEWSWIRE) — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that an Investigational New Drug (IND) application was submitted …
Read more on NASDAQ

 

Cell Therapeutics Looks to Europe for Growth

Filed under: drug treatment news 2011

Alternative drug treatments exist for non-Hodgkin's lymphoma. Rituxan … Spectrum's revenue for Zevalin in 2011 totaled $ 176 million, but that number reflects only U.S. sales because the company didn't gain non-U.S. rights until earlier this year …
Read more on DailyFinance

 

Few doctors know how to treat addiction. A new program aims to change that.

Filed under: drug treatment news 2011

The program, launched in July 2011 and sponsored by the American Board of Addiction Medicine, seeks to attract more doctors to the field and to convince organized medicine to approve the medical treatment of addiction as an officially recognized …
Read more on Washington Post

 

Hepatitis C drugs offer hope for cure

Filed under: drug treatment news 2011

Bzowej helped lead national research into one of the first antiviral treatments that targeted hepatitis C, a protease inhibitor called telaprevir made by Vertex Pharmaceuticals, which was approved by the FDA in June 2011. A similar drug, boceprevir …
Read more on San Francisco Chronicle

 

Synergy Pharmaceuticals Files IND For SP-333, A Developmental Drug For Gastrointestinal Diseases
NEW YORK — Synergy Pharmaceuticals, Inc. , a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that an Investigational New Drug (IND) application was submitted … Read News